Title: An extract of hops (*Humulus lupulus* L.) modulates gut peptide hormone secretion and reduces energy intake in healthy weight men: a randomised, cross-over clinical trial

Author Names: Edward G Walker¹, Kim R Lo¹, Malcolm C Pahl¹, Hyun Sang Shin^{3,4}, Claudia Lang¹, Mark W Wohlers¹, Sally D Poppitt³, Kevin H Sutton², John R Ingram^{1*}

Author Affiliations: ¹The New Zealand Institute for Plant and Food Research Limited, Auckland and ²Lincoln, New Zealand. ³Human Nutrition Unit; School of Biological Sciences, University of Auckland, Auckland, New Zealand. ⁴Current address: Checkmate Therapeutics Inc., Seoul, Korea.

Corresponding author: John Ingram, The New Zealand Institute for Plant and Food Research, Private Bag 92169, Auckland Mail Centre, Auckland 1142, New Zealand. Tel.: +64 9 9257119. Email: john.ingram@plantandfood.co.nz.

Sources of support: Supported by the New Zealand Ministry of Business, Innovation and Employment (MBIE) (Programme # C11X104 – Lifestyle Foods for Appetite Control)

Short running head: Hops extract reduces energy intake

Abbreviations list:

Area under the curve (AUC); bitter taste receptor (T2R); carbon dioxide (CO₂); cholecystokinin (CCK); energy intake (EI); enteroendocrine cell (EEC); gastrointestinal (GI); glucagon like peptide-1 (GLP-1); glucose-dependent insulinotropic polypeptide (GIP); glycated hemoglobin (HbA1c); human bitter taste receptor (hT2R); least significant difference (LSD); pancreatic polypeptide (PP); peptide YY (PYY); profile of mood states (POMS); visual analogue scale (VAS).

Clinical Trial Registry: ACTRN12614000434695 www.anzctr.org.au

Data described in the manuscript, code book, and analytic code will be made available upon request pending application and approval.

1 ABSTRACT

2 Background: Gastrointestinal enteroendocrine cells express a range of chemosensory

3 receptors involved in detecting the chemical composition of food during digestion. These

4 receptors, including bitter taste receptors (T2Rs), may play an important role in regulating gut

5 function and appetite.

6 **Objective:** To establish the ability of Amarasate[®], a bitter supercritical CO₂ extract of hops

7 (*Humulus lupulus* L.) to modify acute energy intake, appetite and hormonal responses and

8 establish a site of action.

9 **Design:** Nineteen healthy-weight (BMI = $23.5 \pm 0.3 \text{ kg/m}^2$) male volunteers completed a

10 randomised three-treatment, double blind, cross-over study with a 1 week washout between

11 treatments. Overnight-fasted participants were cannulated and provided with a standardised 2

12 MJ breakfast meal at 0900h. Treatments comprised a vehicle control (Placebo) or 500 mg of

13 hops extract administered in either delayed release capsules (Duodenal) at 1100 h or quick

release capsules (Gastric) at 1130 h. *Ad libitum* energy intake was recorded at an outcome

15 meal (1200 h) and afternoon snack (1400 h), with blood samples taken and subjective ratings

16 of appetite, gastrointestinal discomfort, vitality, meal palatability and mood assessed

17 throughout the day.

18 **Results:** Compared with placebo, both gastric and duodenal treatments significantly reduced

19 (p < 0.05) total *ad libitum* energy intake by 911 ± 308 kJ and 944 ± 309 kJ, respectively. Both

20 gastric and duodenal treatments significantly increased (p < 0.05) pre-meal ghrelin and post-

21 prandial CCK, GLP-1 and PYY responses while reducing postprandial insulin, GIP and PP

secretion with no significant impact on glycemia. In addition, gastric and duodenal

treatments produced small but significant (p < 0.05) changes in vitality and gastrointestinal

discomfort (e.g. nausea, bloating, abdominal discomfort) with mild-moderate adverse GI

25 symptoms reported in the gastric treatment only. However, no significant treatment effects

26 were observed for any subjective measures of appetite or meal palatability.

Conclusion: Both gastric and duodenal delivery of Amarasate[®] modulate the release of
hormones involved in appetite and glycaemic regulation, providing a potential "bitter brake"
on energy intake in healthy-weight men.

- 31 Keywords: hops, *Humulus lupulus*, appetite, satiety, homeostatic regulation, energy intake,
- 32 ghrelin, cholecystokinin, glucagon-like peptide-1, peptide YY, pancreatic polypeptide, blood
- 33 glucose, insulin, glucose-dependent insulinotropic peptide.

34 INTRODUCTION

54

35 Control of energy intake (EI) is central to the success of interventions designed to manage body weight (1) and the consequences of obesity (2-6). The gastrointestinal (GI) tract 36 37 expresses an array of chemosensory receptors and transporters that provide critical inputs into the acute regulation of energy intake, detecting and relaying to the brain the location, 38 chemical composition and concentration of nutritive and non-nutritive compounds in the gut 39 (7, 8). Obesity and poor weight loss outcomes are associated with impaired gut-brain axis 40 signalling (9-13) which may contribute to overeating and poor adherence to dietary restriction 41 42 (14-17). Approaches that restore or enhance gut-brain axis signalling may address this underlying feedback dysregulation. Indeed, enhancement of gut-brain axis signalling may 43 explain many of the benefits of gastric bypass surgery (18), dietary strategies (e.g. high 44 fibre/protein) and pharmaceutical interventions (19, 20) on the control of EI. Importantly, GI 45 chemosensory mechanisms are readily accessible to dietary manipulation and represent an 46 unexploited source of weight management targets (21-23). 47 Bitter taste receptors (T2R) comprise a family of 25 G protein-coupled receptors that are 48 49 expressed in multiple tissues, including enteroendocrine cells (EEC) of the GI tract (24-26) and are thought to have evolved a chemosensory role in the detection of potential harmful 50 51 substances, limiting their ingestion and absorption (27, 28). In vitro, T2R agonists stimulate 52 the release of peptide hormones, such as ghrelin, cholecystokinin (CCK) and glucagon-like

peptide-1 (GLP-1), from gut enteroendocrine cells (29-32). These gut peptide hormones play

a key role the homeostatic regulation of appetite, energy intake, gut function, hedonic food

55 perceptions and nutient metabolism (33-37). A number of clinical studies using either

56 encapsulation or intragastric and intraduodenal infusion of bitter tastents have demonstrated

57 effects ranging from increased gut peptide secretion, reduced energy intake or rate of gastric

58 emptying, modifications in subjective ratings of hunger and fullness, and altered glycemic

regulation (38-43), although these anorexigeneic effects are inconsistent (43-46),

60 necessitating further investigation of this response.

61 Hops (*Humulus lupulus L*.) contain a range of bitter compounds including α -acids (humulone,

62 adhumulone and cohumulone) and β -acids (lupulone, adlupulone and colupulone) that are

63 known ligands for human bitter taste receptors (47). They have a long history of use as food

64 additives and bittering agents in brewing, as well as in traditional medicine [40, 41] and have

been shown *in vitro* to stimulate Ca^{2+} -dependent CCK release from EEC cells (32).

Administration of hop-derived extracts has also been shown to reduce body weight, fat mass
and improve glucose homeostasis in both rodent (48-55) and human studies (39, 50, 56). In
addition, our laboratory has demonstrated that administration of a supercritical CO₂ hop
extract can reduce subjective ratings of hunger during water-only fasting (57).
Here we investigate the efficacy and GI site of action of Amarasate[®], a bitter supercritical
CO₂ extract of hops, to modify acute energy intake, hormonal and glycaemic responses, and

subjective ratings of appetite, gastrointestinal discomfort, meal palatability and mood in

73 healthy-weight men.

74 METHODS

75 Participants

Healthy-weight men (18–55 years old), with a BMI between 20 and 25 kg/m² were recruited

by advertisement in the Auckland region, New Zealand. A telephone pre-screening interview

to determine eligibility of interested individuals was followed by a screening visit to verify

religibility by measurement of height and weight, assessment of oral bitter taste sensitivity to

the hops extract, and determination of health status by self-report and blood tests (HbA1c,

81 liver function, full blood count, iron status).

82 Participants were excluded if they had a diagnosed medical condition or were on medications

83 known to affect taste, appetite-related parameters, metabolism or gastrointestinal function.

84 Exclusions also applied to participants currently on a weight-loss programme or taking

85 weight-loss medication or who had significant weight loss or gain (>5 kg) within the last six

86 months, were smokers, or had a history of alcohol or drug abuse. Participants with

87 hypersensitivities or allergies to any foods or ingredients included in the study, as well as

those that disliked or were unwilling to consume items listed as study foods or were

unwilling or unable to comply with the study protocol, or who were participating in another

90 clinical intervention trial, were also excluded.

91 All participants provided informed consent prior to clinical trial enrolment. Human ethics

approval was obtained from the Northern B Health and Disability Ethics committee (ref.

93 14/NTB/25) and the trial registered at the Australian and New Zealand clinical trials registry

94 (ref. ACTRN12614000434695). The study was conducted at the Consumer and Products

95 Insights facility of The New Zealand Institute for Plant and Food Research Limited

96 (Auckland, New Zealand) in March–June 2014.

97 Study design

A randomized, double-blind, placebo-controlled, 3-treatment crossover study design was
used to determine the efficacy and GI site of action of Amarasate[®] to modify acute energy
intake, appetite and postprandial hormonal responses in healthy-weight men. The three
treatment arms (Supplemental Table 1) were: Amarasate[®] (500 mg) targeted for release into
the stomach (gastric), Amarasate[®] (500 mg) targeted for release in the proximal small
intestine (duodenum), and a vehicle control (placebo). Randomisation was conducted using a
3x3 Latin square balanced for treatment order and carryover effects (58, 59).

- 105 Three one-day visits were required with a washout period of at least one week between visits.
- 106 The daily protocol is shown in **Figure 1**. Food intake and subjective measures of appetite,
- 107 gastrointestinal discomfort, vitality, meal palatability and mood were assessed during fully
- 108 supervised study days using standard methodology as per the recommendations of Blundell et
- 109 al. (60).

110 Treatments

- 111 To maintain treatment blinding, all treatments contained two sets of opaque capsules, one set
- administered at 1100 h were delayed release capsules (DRCapsTM, size 0, Capsugel, NJ,
- 113 USA) designed to release their contents approximately 50–70 min after ingestion, increasing
- the likelihood of delivery to the duodenum (61). The second set given at 1130 h were
- standard hydroxypropyl-methylcellulose capsules (VcapsTM, size 0, Capsugel) designed to
- 116 release in the stomach. The timing of capsule administration was chosen so that the treatment
- 117 capsules would probably have released their contents in the stomach or duodenum before the
- 118 *ad libitum* lunch (1200 h).
- 119 The three treatment groups were as follows: **Placebo** two vehicle control delayed-release
- 120 capsules (1100 h) followed by two vehicle control standard-release capsules (1130 h);
- 121 Gastric two vehicle control delayed-release capsules (1100 h) followed by two Amarasate[®]
- standard-release capsules (1130 h); **Duodenum** two Amarasate[®] delayed-release capsules
- 123 (1100 h) followed by two vehicle control standard-release capsules (1130 h).
- 124 Each Amarasate[®] treatment comprised two capsules, each containing 250 mg of a
- 125 commercially available food-safe supercritical CO₂ extract of hop cones (*Humulus lupulus* L.
- 126 'Pacific Gem') sourced from New Zealand Hops Ltd, NZ, mixed with 125 mg of canola oil
- as an excipient (a 2:1 hops:oil ratio). The vehicle control capsules utilised in the placebo
- treatment and for blinding in the gastric and duodenal treatments contained 125 mg of canola

- 129 oil. All capsules were filled in-house using the Capsugel Profiller system (Capsugel,
- 130 Morristown New Jersey, USA) with a coefficient of variation of 2% for loading accuracy.
- 131 The α and β -acid composition of the hop supercritical CO₂ extract comprised 51.5% total α -
- acids (cohumulone 21.1%, humulone 22.3% and adhumulone 8.2%), and 28.3% total β -acids
- (colupulone 19.7%, lupulone 6.0% and adlupulone 3.1%) as determined by high
- 134 performance liquid chromatography (HPLC) (Supplemental Figure 1) with reference to the
- 135 American Brewing Association ICE-3 standard as described in (62). The α and β -acid
- 136 composition of the Amarasate[®] formulation has previously been shown to remain stable over
- the duration of use in the current study (57).

138 Study visits 1–3

139 Participants arrived at the study facility by 0730 h on test days in an overnight fasted state (no

140 food or drinks apart from water since 2200 h) having abstained from excessive exercise or

alcohol consumption the day before. An indwelling venous cannula was inserted into a

142 forearm vein for repeated blood collection. Figure 1 shows the study visit protocol including

timing of meals, treatment administration, and the collection of blood and behavioural

144 measures. During free time between the meals and questionnaires, participants remained

inside the facility but were free to read, watch TV or access the internet on their own devices.

- 146 Participants were free to leave the facility after completion of the final study questionnaire
- and removal of the cannula at 1600 h.



149 Figure 1. Protocol for study visits 1–3. Participants arrived fasted (0730 h), were cannulated and provided 150 with a fixed energy (2 MJ) breakfast (0900 h) that they had to complete. Treatments along with matched 151 placebo capsules targeting the duodenum (D) or gastric (G) compartments were administered at 1100 h (T=0 min) and 1130 h (T= 30 min), respectively. Participants were provided with ad libitum lunch (1200 h) and 152 153 snack (1400 h) outcome meals and directed to eat until comfortably full. Blood samples (B) and VAS 154 ratings (V) of appetite, thirst, vitality and gastrointestinal discomfort related-measures were collected 155 throughout the day. Ratings of meal palatability (P) were assessed using VAS scales immediately after every 156 meal. Mood state (M) were assessed in the morning and afternoon using the Profile of Mood State 157 questionnaire. VAS, visual analogue scale; Ad lib, Ad libitum.

158 Fixed energy breakfast, ad libitum meals, and EI

159 The fixed energy (2 MJ) breakfast (Supplemental Table 2) consisted of puffed rice cereal with low fat milk and white bread with margarine and jam. Participants were instructed to 160 161 consume the entire breakfast within 15 min (verified by visual inspection). The outcome ad *libitum* lunch (1200 h, T= 60 min) was a savoury buffet restricted to a beef and tomato pasta 162 sauce and boiled pasta spirals with water (250 mL). Ham sandwiches, cut into quarters with 163 the crusts removed, were provided for the outcome afternoon snack (1400 h, T=180 min) 164 165 with water (250 mL). Both *ad libitum* meals were provided in excess, with participants instructed that they had 30 minutes to eat until they were comfortably full. To minimise 166 distractions, all meals were provided in individual booths with participants instructed not to 167 talk, read or use mobile phones or electronic devices and to remain in the booth for the 168 designated time. Meals were weighed by two separate observers before and after 169 consumption and energy, fat, carbohydrate, and protein intake were calculated with the use of 170 the dietary software program FoodWorks (Professional Edition, version 5; Xyris Software). 171 All meals were designed to have low phytochemical content to minimise non-specific effects 172 on appetite (63). 173

174 Behavioural measures

Visual analogue scales (VAS) were used to assess subjective feelings of hunger, fullness, 175 176 satiety, and prospective consumption following the methodology outlined in Blundell et al. (60, 64). Additional VAS were used to assess thirst; measures of vitality (energy levels and 177 relaxation); GI discomfort including nausea, urge to vomit, bloating, abdominal discomfort, 178 and heartburn (adapted from (65)); and meal palatability (64) (pleasantness, visual appeal, 179 smell, taste, aftertaste and overall palatability). The VAS questions and anchor statements are 180 provided in **Supplemental Table 3**. Participants marked their responses by placing a vertical 181 line across the 100-mm scale according to subjective feelings, with responses recorded to the 182 183 nearest mm.

- 184 Changes in mood states were assessed at 1000 h (T = -60) and 1530 h (T = 270) using the
- original version of the Profile of Mood States (POMS) questionnaire (66), a 65-item
- 186 inventory of six subscales: tension-anxiety, depression-dejection, anger-hostility, vigour-
- 187 activity, fatigue-inertia, and confusion-bewilderment. Participants rated "How are you feeling
- right now" for each mood descriptor on a 5-point scale anchored by 1 = "not at all" and 5 =
- 189 "extremely". The total mood disturbance score was computed by adding the five negative

- subscale scores (tension, depression, anger, fatigue, confusion) and subtracting the vigourscore.
- 192 The occurance of adverse symptoms/events were recorded for each study visit with
- 193 participants describing symptoms and their severity using a three-point scale of mild,
- 194 moderate or severe. Participants were also asked to recall any delayed symptoms/events
- 195 during the washout period at their next visit.

196 Blood measurements

- 197 Blood for peptide hormones analysis was collected into pre-chilled 5-mL EDTA tubes (BD
- 198 Vacutainer[®], USA) containing a dipeptidyl-aminopeptidase IV inhibitor (25 µL of a 2 mM
- solution of Diprotin A, Peptides International, Osaka, Japan) and a general protease inhibitor
- 200 cocktail (Complete Mini EDTA-free protease inhibitor, Roche, Basel, Switzerland) (182 µL
- of solution made up of one tablet in 2 mL of water). Blood for plasma glucose analysis was
- 202 collected into sodium fluoride/potassium oxalate Vacutainer[®] tubes (BD, USA). Upon
- collection samples were immediately centrifuged (1500xg for 10 min at 4°C) and the plasma
- snap frozen on dry ice before storage at -80° C until analysis.
- 205 Ghrelin (active), GLP-1 (active), PYY (total), insulin, GIP (total) and pancreatic polypeptide
- 206 (PP) concentrations were measured using a multiplexed magnetic bead assay (HMHMAG-
- 207 34K; Merck-Millipore, Massachusetts USA). Samples were assayed in duplicate and plates
- 208 read using a Magpix[™] system (Luminex, USA) with concentrations determined using a 5-
- 209 parameter curve fit in Analyst 5.1 (Miliplex, USA). Plasma CCK concentrations were
- 210 determined in duplicate by radioimmunoassay (EURIA-CCK, Eurodiagnostica, Sweden) as
- 211 per the manufacturer's instructions, with CCK standards formulated in pooled charcoal
- stripped human plasma. Assay QC data are given in **Supplementary Table 4**. Plasma
- 213 glucose was analysed by Lab Services (North Shore Hospital Lab Services, Auckland) using
- the hexokinase method on a Dimension[®] Vista 1500 (Siemens AG, Erlangen, Germany).

215 Statistical Analysis

- A completers only analysis was used to address missing data. Time profile data including
- 217 VAS ratings and blood biomarkers were analysed with the use of a linear mixed model (SAS
- software, PROC GLIMMIX function, version 9.4; SAS Institute Inc.) with treatment, sample
- 219 number, visit number and and treatment order (one of six possible treatment sequences
- allocated to each subject) and their respective interactions included as fixed effects. Fisher's
- protected LSD was used to account for multiple testing. Where there was evidence of a main

treatment or treatment x time interaction (p < 0.05), F-tests for treatment differences at each time point were conducted using the 'slice' command. Where these were significant (p < 0.05), Fisher's protected LSD *post hoc* analysis was used for pairwise comparisons between treatments.

Area under the curve (AUC) data were calculated from time 0 to 270 min for blood

biomarkers, and from 0 to 300 min for VAS measures, and analysed using a linear mixed

228 model (SAS 9.4) with treatment, visit number and and treatment order as fixed effects..

229 Where there was evidence of a main treatment effect (p < 0.05), Fisher's protected LSD was

used to account for multiple testing of pairwise comparisons between treatments. EI data

were analysed in the same way, with models fitted separately for the snack, lunch, and total

kJ intake measures. For meal palability measures an additional fixed factor of meal

233 (breakfast, lunch and snack) was included in the linear mixed model, while analysis of POMS

subscales included the fixed factor of time (pre/post). Results are presented as means \pm SEM;

if required, data were log transformed before analysis, with results presented as back-

transformed means \pm SEM. Statistical significance was assessed at p <0.05.

237 **Results**

238 Participants

Of the 20 healthy-weight male participants randomly assigned into the trial, 19 completed all three arms of the study, with one participant excluded for failure to comply with study protocol (see CONSORT flow diagram, **Supplemental Figure 2**). Characteristics of the 19 participants included in the final analysis of energy intake and subjective behavioural measures are shown in **Table 1**. A second participant was excluded from blood sample analysis only because of repeated cannula failures and inability to obtain sufficient blood volume. Hence, data on blood biomarkers is presented for 18 participants.

	Mean ± SD	Range
Age, y	28.9 ± 10.4	18–54
Height, m	1.80 ± 0.08	1.66–1.95
Body weight, kg	76.1 ± 8.3	60.4–94.5
BMI, kg/m ²	23.5 ± 1.4	20.9–25.0
Ethnicity ² :		
New Zealand European	13	
Maori/Pacifica	2	
Asian	3	
Other	1	

247 Table 1. Characteristics of the 19 male participants who completed all three treatment arms¹

²⁴⁸ ¹All measurements were recorded at the screening visit. ²Ethnicity was assessed by self-report.

250 EI at ad libitum meals

251 The effects of treatment on EI at the outcome *ad libitum* lunch and snack meals are shown in

Figure 2. Total EI from the two outcome meals showed a highly significant effect of

253 treatment ($F_{2,34} = 6.0$, p = 0.006), with both the gastric (4320 ± 350 kJ, p = 0.015) and

duodenal ($4287 \pm 350 \text{ kJ}$, p= 0.012) treatments resulting in significant reductions compared

with the placebo (5231 \pm 350 kJ). A significant effect of treatment (F_{2,34} = 4.0, p = 0.027) was

observed at the *ad libitum* snack with a reduction of EI in the duodenal treatment (1423 ± 199)

kJ, p=0.044) compared with the placebo (2018 ± 199 kJ), while the values in the gastric

treatment (1452 \pm 199 kJ, p=0.056) just failed to reach statistical significance. EI at the *ad*

libitum lunch showed no significant effect of treatment.

²⁴⁹

261



262

263 Figure 2. The effect of treatment on *ad libitum* energy intake (kJ) at the outcome lunch (1200 h), snack (1400 h) and the combined intake (Total intake). Treatments comprised either a vehicle 264 265 control (Placebo) or a formulated hops extract (Amarasate[®]) designed to release in the stomach (Gastric) or in the proximal small intestine (Duodenum). Analysis was conducted using the Mixed 266 267 procedure (SAS 9.4) with treatment, visit number and treatment order as factors. A significant effect of treatment was observed for both the snack ($F_{2,34} = 4.0, p = 0.027$) and for total intake ($F_{2,34}$ 268 269 = 6.0, p = 0.006). Fisher's LSD post hoc pairwise analysis demonstrated a significant (p = 0.044) 270 reduction in energy intake for the duodenal treatment compared with the placebo at the snack and 271 for both the gastric (p = 0.015) and duodenal (p = 0.012) treatments compared with the placebo 272 when assessed as total intake. Values are means \pm sem, (n = 19). * p < 0.05.

273 **Blood parameters**

274 Ghrelin, CCK, GLP-1 and PYY

275 The effects of treatment on plasma concentrations and AUC_{0-270 min} responses of the appetite

regulating hormones ghrelin, CCK, PYY and PP are shown in **Figure 3A–D**. All four peptide

- 277 hormone profiles exhibited predictable changes driven primarily by the timing of meals.
- 278 *Ghrelin*: Plasma concentrations of the orexigenic hormone ghrelin exhibited a significant
- treatment x time interaction ($F_{30,440} = 1.74$, p = 0.010). Subsequent post hoc analysis
- demonstrated a significant increase in ghrelin in both gastric (p = 0.0009) and duodenal (p =
- 0.004) treatments compared with the placebo, immediately prior to the *ad libitum* lunch (T =
- 60). No significant differences were detected between any of the treatments at any post-lunch
- time point or for the AUC_{0-270 min} response (**Figure 3A**).
- 284 *CCK*: A significant main effect of treatment ($F_{2,70} = 5.8$, p < 0.005) and treatment x time
- ($F_{30,481} = 1.9, p = 0.004$) interaction were observed for plasma concentrations of the
- anorexigenic hormone CCK, with a similar pattern of enhanced postprandial CCK secretion
- observed in both the gastric and duodenal treatments compared with the placebo (Figure 3B).
- 288 *Post hoc* analysis demonstrated that plasma CCK concentrations were significantly increased
- (p < 0.05) in both Amarasate[®] treatments compared with the placebo at T = 90, 150, 180,

- 290 210, and 240 min. Significant increases (p < 0.05) were also seen at T = 105 and 120 min in
- the gastric and at T = 135 and 270 min in the duodenal treatments compared with the
- 292 placebo. A significant difference between the gastric and duodenal treatments was observed
- at the 90-min time point only (p = 0.024).
- A significant effect of treatment was also seen for the CCK AUC_{0-270 min} responses ($F_{2,32}$ =
- 8.66, p = 0.001), with increased hormone secretion observed in both the duodenal (p = 0.002)
- and gastric (p < 0.001) treatments compared with the placebo (**Figure 3B**). Gastric and
- 297 duodenal treatments did not differ significantly from each other.
- 298 GLP-1: Plasma concentrations of the insulin secretagogue and anorexigenic hormone GLP-1
- 299 exhibited considerable inter-individual variability (including one individual who exhibited
- 300 approximately forty times average baseline levels), though a significant treatment x time
- interaction ($F_{30,422} = 1.5$, p = 0.038) was observed. *Post hoc* analysis demonstrated an
- enhanced (p < 0.05) postprandial response to the *ad libitum* lunch in the gastric treatment at T
- 303 = 90, 105 and 150 min compared with the placebo (Figure 3C). The duodenal treatment
- elicited a similarly enhanced postprandial response, with significant (p < 0.05) increases at T
- = 105, 210 and 240 min compared with the placebo. Gastric and duodenal treatments did not
- differ significantly from each other at any time point. No evidence for a main effect of
- treatment was seen for GLP-1 AUC $_{0-270 \text{ min}}$ responses (**Figure 3C**).
- 308 *PYY*: A significant effect of treatment ($F_{2,35} = 7.6$, p = 0.002) and a treatment x time ($F_{30,475} =$
- 1.5, p = 0.042) interaction were observed for plasma concentrations of the anorexigenic gut
- hormone PYY (Figure 3D). Though considerable inter-individual variability was observed in
- baseline concentrations (two participants were ~10 fold higher than average). *Post hoc*
- analysis demonstrated that when compared with the placebo, gastric delivery of Amarasate[®]
- produced significant increases in PYY immediately prior to the lunch (T=60), with
- differences becoming more apparent post lunch through to the end of the session (T = 90-270
- min, p < 0.05). The PYY response to the duodenal treatment was significantly elevated
- relative to the response in the placebo treatment only after the *ad libitum* snack at T=210 and
- 240 (p < 0.05) minutes. A significant difference between gastric and duodenal treatments was
- also observed at T = -120, 135 and 150 min (p < 0.05).
- A significant effect of treatment was seen for the PYY AUC_{0-270 min} responses ($F_{2,32} = 11.14$, p
- < 0.001), with significantly increased PYY secretion observed in the gastric compared with
- both the duodenal (p = 0.027) and placebo (p < 0.0001) treatments. PYY release was also

significantly (p = 0.023) greater in the duodenal treatment than in the placebo (**Figure 3D**)



323

324 Figure 3 Plasma concentrations of (A) ghrelin (active); (B) cholecystokinin (CCK); (C) glucagon like 325 peptide-1 (active) (GLP-1) and (D) peptide YY (PYY) following administration of a control (Placebo) or 326 Amarasate® targeted to either the small intestine (Duodenal) or stomach (Gastric) using delayed-release 327 or standard capsules, respectively. Arrows indicate capsule administration; grey bars indicate the time 328 allowed for the 2 MJ fixed energy breakfast and the *ad libitum* lunch and snack. Analysis was conducted 329 using the mixed procedure (SAS 9.4) with treatment, time, visit number and treatment order as factors. 330 Significant effects of treatment (B and D, p < 0.005) and a treatment x time interaction (A and C, p < 0.04) 331 were observed. Fisher's LSD *post hoc* pairwise comparisons: gastric v placebo (*p < 0.05, **p < 0.01, *** p 332 < 0.001); duodenal v placebo (^p < 0.05, ^^ p < 0.01, ^^^ p < 0.001); gastric v duodenal (*p < 0.05, ** p < 333 0.01, ^{###} p < 0.001). Histograms show effect of treatment on AUC₀₋₂₇₀ min for each hormone from 0 to 270 334 min. Analysis was conducted using the mixed procedure (SAS 9.4) with treatment, visit number and 335 treatment order as factors. A significant effect of treatment was observed for B and D (p = 0.001) only, 336 with letters denoting significantly (p < 0.05) different means. Values are means ± SEM; n = 18. Ad lib, ad 337 libitum.

338 *Glucose, Insulin, GIP and PP*

339 Effects of treatment on plasma concentrations and AUC_{0-270 min} responses of glucose, insulin,

- GIP and PP are shown are shown in **Figure 4A–D**.
- 341 *Glucose:* Changes in glucose with time (**Figure 4A**) suggest that Amarasate[®] treatment
- modified postprandial hyperglycemia following the *ad libitum* lunch (T = 90) only. However,
- 343 no significant main effect of treatment or treatment x time interaction was observed for blood
- 344 glucose concentrations or in the glucose $AUC_{0-270 \text{ min}}$ response.
- 345 *Insulin:* Plasma insulin concentrations exhibited a significant effect of treatment ($F_{2,39} = 8.6$,
- 346 p < 0.001) and a treatment x time (F_{30,332} = 1.8, p = 0.011) interaction (**Figure 4B**). *Post hoc*
- analysis demonstrated that insulin responses to the *ad libitum* lunch and snack showed a
- significant reduction (p < 0.05) following the gastric and duodenal treatments at T= 90, 105,
- 120, 180 and 210 min compared with the placebo. This difference extended out to T = 240
- 350 min for the gastric treatement only. Insulin responses in the gastric and duodenal treatments

did not differ significantly from each other at any time point. A highly significant effect of

- treatment ($F_{2,32} = 10.8$, p = 0.0003) was also observed in insulin AUC_{0-270 min} responses
- 353 (Figure 4B), with a reduction in postprandial insulin secretion following the gastric (p =
- 0.0013) and duodenal (p = 0.0001) treatments compared with the placebo. Insulin AUC₀₋₂₇₀
- 355 _{min} responses in the gastric and duodenal treatments did not differ significantly from each
- 356 other.
- GIP: Plasma concentrations of the insulin secretagogue GIP exhibited a significant effect of 357 treatment ($F_{2,65} = 6.8$, p < 0.002) and a treatment x time ($F_{30,517} = 1.7$, p = 0.010) interaction. 358 Post hoc analysis demonstrated that the postprandial response to the ad libitum lunch and 359 snack were significantly reduced in both the gastric and duodenal treatments compared with 360 the placebo from T = 90 to 240 min (p < 0.050). Gastric and duodenal treatments did not 361 362 differ significantly from each other at any timepoint. GIP AUC_{0-270 min} responses (Figure **4C**) exhibited a highly significant effect of treatment ($F_{2,32} = 15.5$, p <0.0001), with 363 reductions in postprandial GIP secretion following the gastric (p < 0.0001) and duodenal (p364 < 0.0001) treatments compared with the placebo. Gastric and duodenal treatments did not 365 differ significantly from each other. 366

367 *PP:* Plasma concentrations of the pancreatic hormone PP exhibited a significant effect of 368 treatment ($F_{2,69} = 8.8$, p = 0.0004) and a treatment x time interaction ($F_{30,491} = 1.91$, p =369 0.003), increasing following meals in all treatment groups (**Figure 4D**). *Post hoc* analysis

- demonstrated that postprandial PP responses were significantly (p < 0.05) reduced in both the
- gastric (T = 90–240 min) and duodenal (T = 105-210 min) treatments compared with the
- 372 placebo. Duodenal and gastric treatments did not differ significantly from each other at any
- 373 timepoint.
- A highly significant effect of treatment ($F_{2,32} = 11.6$, p = 0.0002) was seen for the PP AUC₀₋
- $_{270 \text{ min}}$ responses, with reduced hormone secretion observed in both the duodenal (p = 0.0096)
- and gastric (p < 0.0001) treatments compared with the placebo (**Figure 4D**). Gastric and
- 377 duodenal treatments did not differ significantly from each other.





Figure 4. Plasma concentrations of (A) glucose; (B) insulin; (C) glucose-dependent insulinotropic polypeptide (GIP); and (D) pancreatic polypeptide (PP) following administration of a control (Placebo) or Amarasate® targeted to either the small intestine (Duodenal) or stomach (Gastric) using delayedrelease or standard capsules, respectively. Arrows indicate capsule administration; grey bars indicate the time allowed for the 2 MJ fixed energy breakfast and the *ad libitum* lunch and snack. Analysis was conducted using the mixed procedure (SAS 9.4) with treatment, time, visit number and treatment order as factors. A significant effect of treatment (B–D, p < 0.003) was observed. Fisher's LSD post hoc pairwise comparisons: gastric v placebo (*p < 0.05, ** p < 0.01, *** p < 0.001); duodenal v placebo (^p < 0.05, ^^ p < 0.01, ^^^ p < 0.001); gastric v duodenal (*p < 0.05, ** p < 0.01, *** p < 0.001). Histograms show effect of treatment on AUC0-270 min for each hormone from 0 to 270 min. Analysis was conducted using the mixed procedure (SAS 9.4) with treatment, visit number and treatment order as factors. A significant effect of 391 treatment was observed for B–D (p < 0.001) only, with letters denoting significantly (p < 0.05) different 392 means. Values are means ± SEM; n = 18. Ad lib, ad libitum.

393 VAS – appetite

- 394 Effects of treatment on the subjective ratings of hunger, fullness, prospective consumption,
- satisfy and thirst over time and as $AUC_{0-300 \text{ min}}$ are shown in Figure 5A–E. A predictable
- pattern driven by meal timing was seen in all VAS profiles. However, there was no evidence
- 397 for a significant main effect of treatment or treatment x time interaction for any of the
- 398 changes in VAS appetite profiles or in $AUC_{0-300 \text{ min}}$.



400 Figure 5 VAS ratings of (A) hunger; (B) fullness; (C) prospective consumption; (D) satiety; and (E) thirst 401 following administration of a control (Placebo) or Amarasate® targeted to either the small intestine 402 (Duodenal) or stomach (Gastric) using delayed-release or standard capsules, respectively. Arrows 403 indicate capsule administration; grey bars indicate the time allowed for the 2 MJ fixed energy breakfast 404 and the *ad libitum* lunch and snack. Analysis was conducted using the mixed procedure (SAS 9.4) with 405 treatment, time, visit number and treatment order as factors. No main effect of treatment or a treatment 406 x time interaction was observed for any measure. Histograms show mean AUC0-300 min for each VAS 407 measure from 0 to 300 min. Analysis was conducted using the mixed procedure (SAS 9.4) with 408 treatment, visit number and treatment order as factors. No significant effects of treatment were seen. 409 Values are means ± SEM; n = 19. Ad lib, ad libitum.

410 VAS – vitality

411 Effects of treatment on subjective ratings of energy and relaxation are shown in

412 Supplemental Figure 3A–B. Ratings of energy exhibited a significant treatment effect (F_{2,98}

- 413 = 3.29, p = 0.041), with *post hoc* analysis demonstrating significantly (p < 0.050) lower
- 414 energy ratings in the duodenal treatment at T = 120, 135, 150 and 270 min, and in the gastric
- 415 treatment at T = 150 and 270 min, compared with the placebo. A signicant treatment effect
- 416 $(F_{2,32} = 4.65, p = 0.017)$ was also seen for AUC_{0-300 min} responses, with lower ratings for the
- 417 gastric (p = 0.019) and duodenal (p = 0.009) treatments compared with the placebo
- 418 (Supplemental Figure 3A). Subjective ratings of relaxation were similar throughout the day,
- 419 with no significant main effects of treatment or treatment x time interactions (**Supplemental**
- 420 **Figure 3B**).

421 VAS – Gastrointestinal discomfort

- 422 Effects of treatment on subjective ratings of nausea, urge to vomit, bloating, abdominal
- 423 discomfort and heartburn are shown in **Figure 6A–E**.
- 424 *Nausea:* Ratings of nausea (**Figure 6A**) exhibited a significant treatment effect ($F_{2,124} = 5.5$, p
- 425 = 0.005), with *post hoc* analysis demonstrating significantly (p < 0.050) higher nausea ratings
- 426 in the duodenal treatment at T = -30, 180, 210 and 240 min, and in the gastric treatment at T
- 427 = 150 and 180 min, compared with the placebo. Signifcant differences between the gastric
- 428 and duodenal treatments were seen at T = -30 and 240 min. A significant treatment effect
- 429 ($F_{2,32} = 10.9$, p = 0.0002) on AUC_{0-300 min} responses was also observed, with lower ratings in
- 430 the gastric (p = 0.006) and duodenal (p < 0.0001) treatments than in the placebo.
- 431 *Urge to vomit:* There was no evidence for a significant main effect treatment or treatment x
- time interactions in the urge to vomit (**Figure 6B**). However, a significant treatment effect
- 433 ($F_{2,32} = 3.95$, p = 0.029) on AUC_{0-300 min} responses was seen, with a small increase in the urge
- 434 to vomit (p = 0.009) in the duodenal treatment compared with the placebo.

- 435 *Bloating:* A significant main effect of treatment ($F_{2,127} = 6.83$, p = 0.002) was seen for
- 436 subjective ratings of abdominal bloating (Figure 6C). Post hoc analysis demonstrated
- 437 significantly (p < 0.050) higher ratings of abdominal bloating in the duodenal treatment at T
- 438 = 90-150 and 240 min, and in the gastric treatment at T = 90, 135 and 150 min, than in the
- 439 placebo (**Figure 6C**). A significant treatment effect ($F_{2,32} = 7.8$, p = 0.002) was also seen on
- 440 AUC_{0-300 min} responses, with a small increase in bloating in the duodenal (p = 0.001) and
- 441 gastric (p = 0.020) treatments compared with the placebo.
- 442 *Abdominal discomfort:* A significant main effect of treatment ($F_{2,116} = 5.65$, p = 0.005) was
- seen for ratings of abdominal discomfort (Figure 6D), with *post hoc* analysis demonstrating
- significantly (p < 0.050) higher abdominal discomfort ratings in the duodenal treatment at T
- 445 = 15, 210 and 240 min, and in the gastric treatment at T = 210 min, than in the placebo.
- 446 Signifcant differences between gastric and duodenal treatments were seen at T = 15 min.
- 447 However, there was no evidence for a significant effect of treatment on $AUC_{0-300 \text{ min}}$.
- 448 *Heartburn:* No significant main effects of treatment or treatment x time interactions were
- observed for ratings of heartburn or AUC_{0-300 min} response (**Figure 6E**).

450



453 Figure 6 VAS ratings of (A) nausea; (B) urge to vomit; (C) bloating; (D) abdominal discomfort; and (E) 454 heartburn following administration of a control (Placebo) or Amarasate® targeted to either the small 455 intestine (Duodenal) or stomach (Gastric) using delayed-release or standard capsules, respectively. 456 Arrows indicate capsule administration; grey bars indicate the time allowed for the 2 MJ fixed energy 457 breakfast and the *ad libitum* lunch and snack. Analysis was conducted using the mixed procedure (SAS 458 9.4) with treatment, time, visit number and treatment order as factors. A significant effect of treatment 459 was observed for A, C and D (p < 0.010). Fisher's LSD *post hoc* pairwise comparisons: gastric v placebo 460 (*p < 0.05, ** p < 0.01, *** p < 0.001); duodenal v placebo (^p < 0.05, ^^ p < 0.01, ^^^ p < 0.001); gastric v

461	duodenal ($^{*}p < 0.05$). Histograms show effect of treatment on AUC _{0.300} min for each VAS scale from 0 to
462	300 min. Analysis was conducted using the mixed procedure (SAS 9.4) with treatment, visit number and
463	treatment order as factors. A significant effect of treatment was observed for A–C ($p < 0.05$), with letters
464	denoting significantly (p < 0.05) different means. Values are means ± SEM; n = 19. Ad lib, ad libitum.

465 *VAS – Meal palatability*

There was no evidence for a main effect of treatment on VAS ratings of pleasantness, visual
appeal, smell, taste, aftertaste, or overall palatability for the fixed-energy breakfast or the *ad libitum* lunch and snack outcome meals (Supplemental Figure 4).

469 *Profile of mood states (POMS)*

470 The effects of treatment on the six mood subscales and total mood disturbance measured

471 prior to treatment administration (Pre) and in the POMS questionnaire are shown in

472 **Supplemental Figure 5A–G**. Only depression-dejection ($F_{2,83} = 3.4$, p = 0.038) and anger-

hostility ($F_{2,83} = 6.14$, p = 0.003) exhibited a significant main effect of treatment. *Post hoc*

analysis demonstrated a small but significant (p = 0.011) increase (2.3 ± 1.2) in scoring of

depression-dejection following the gastric treatment compared with the placebo (1.5 ± 1.2)

476 (Supplemental Figure 5B). Small but significant increases in ratings of anger-hostility were

477 also seen following the gastric (2.2 ± 1.2) treatment compared with the duodenal (1.5 ± 1.2) ,

478 p = 0.016) and placebo (1.4 ± 1.2, p = 0.004) treatments (**Supplemental Figure 5C**).

479 However, these small changes in mood state may be a reflection of social and envrionmental

480 interactions e.g. self-entertainment activities such as watching TV, reading and socialising.

481 *Adverse symptoms*

The numbers of participants reporting adverse symptoms such as loose stool/diarrhea, nausea, 482 483 rumbling or upset stomach, bloating and headache during the study day, and their subjective ratings of severity (mild, moderate or severe) are shown in Table 2. The primary analysis of 484 485 all 19 participants revealed a total of 14 adverse symptoms, the majority of which (93%) occurred while on the gastric treatment. No adverse symptoms were reported while on the 486 placebo treatment and only one individual reported a reduced frequency of defecation in the 487 week following the duodenal treatment (washout period), which may not have been 488 attributable to the treatment, given the delay. The participant excluded for failure to comply 489 with the study protocol experienced moderate-intensity loose stools and nausea in both 490 491 gastric and duodenal treatments and was included in a separate analysis (in brackets) of 20 participants for completeness. 492

493	Table 2. The effects of treatment on numbers of reported adverse symptoms and range of self-reported
494	intensities ¹ .

	Placebo	Gastric	Duodenal
Nausea	-	2/19 (3/20) ² mod	-(1/20)²mod
Loose stool/diarrhea	-	6/19 (7/20) ² mild-mod	-(1/20) ² mod
Stomach rumbling	-	1/19 mild	-
Upset stomach	-	1/19 mild	-
Bloating	-	2/19 mod	-
Headache	-	1/19 mild	-
Frequency of defecation	1 -	-	1/19 mod ³

⁴⁹⁵ ¹ Severity of adverse events was reported using a three-point scale of mild, moderate (mod) or severe over the ⁴⁹⁶ study visit and washout period for each treatment. Treatments comprised a vehicle control (Placebo) or ⁴⁹⁷ Amarasate[®] targeted to either the small intestine (Duodenal) or stomach (Gastric) using delayed-release or ⁴⁹⁸ standard capsules, respectively. ²The participant excluded for failure to comply with the study protocol ⁴⁹⁹ experienced moderate-intensity loose stools and nausea in both gastric and duodenal treatments and was included ⁵⁰⁰ in the adverse symptom reporting as a separate analysis (in brackets) with all n=20 participants. ³One participant ⁵⁰¹ noted a reduced frequency of defecation over the following week washout period.

502 4. Discussion

503 Gastrointestinal delivery of a bitter hop extract significantly decreased energy intake and

504 increased appetite-suppressing CCK, PYY and GLP-1 plasma concentrations. These changes

505 occurred without significant effects on subjective measures of appetite or the hedonic

506 properties of the test meals. However they were accompanied by small increases in

subjective ratings of nausea, bloating, urge to vomit and abdominal discomfort, all of which

are expected to decrease EI, and may be confounders. The magnitude of total EI suppression

509 (18%) is significant in the context of weight management applications (67) and compares

favourably with results from previous studies in humans (0-22%) that have used either

encapsulation, intragastric or intraduodenal delivery of a variety of bitter tastants (38, 40, 42,

512 43, 46, 68, 69).

513 The current study supports a mechanism of action involving enhanced and sustained release

of the anorexigenic gut hormones CCK, GLP-1 and PYY from intestinal EECs. All three gut

515 peptide hormones play a key role in the homeostatic regulation of energy intake, appetite and

- 516 GI function (reviewed in (70)) and have previously been shown to respond to T2R ligands
- 517 (29, 30, 44, 48). Maximum post-prandial increases in CCK following Amarasate[®] treatments
- 518 were almost 6-fold that of baseline and in the upper range reported for dietary interventions

519 (0.5–7.9 fold) (71)). Greater variablity between individuals and smaller fold changes were

520 observed for GLP-1 (2.4 fold) and PYY (1.8 fold). A recent meta-analysis of CCK, GLP-1

and PYY infusion studies (71) that proposed that the minimum fold changes required to

because *ad libitum* energy intake were 3.6, 4.0 and 3.1-fold, respectively.

A significant enhancement of the orexigenic hormone ghrelin response prior to the lunch was also seen for both gastric and duodenal targetting of the hop extract. This is consistent with the duodenum being a source of ghrelin secretion, second only to the stomach (72, 73),

although pyloric reflux may also play a role (74). Gavage of T2R agonists has also been

shown to stimulate the secretion of ghrelin in mice, resulting in a temporary increase in food

528 intake (75). However, our results contrast with several recent reports of either unchanged or

529 supressed ghrelin following intragastric infusion of T2R agonists (quinine, denatoium

benzoate) in humans (41, 76), indicating potential T2R specificity in this response. The

531 mechanism(s) by which T2R agonists stimulate ghrelin secretion are poorly understood, as

532 gastric ghrelin-secreting cells are of the closed type and do not directly contact the GI lumen.

533 It is also noteworthy that there was no significant treatment-induced difference in VAS

measurements relating to appetite despite the significant decrease in energy intake seen with

both hop treatments. Although correlations between subjective assessments (e.g. hunger) and

behavioural effects (e.g. energy intake) are often observed, they assess fundamentally

537 different things, have been reported to show weak correlations, and do not always concur (77,

53878). Previous studies using either gastric or duodenal delivery of T2R agonists have shown

effects on subjective measures of appetite in both men (79-81), and women (41, 82), although

540 many studies show no response (43-46). Interestingly, participants in the current study did

541 achieve similar feelings of fullness at the *ad libitum* test meals after consuming less food

542 when taking both hop treatments compared with the placebo. Viewed in this context,

543 Amarasate[®] treatment may modulate early satiety, which is associated with impaired gastric
544 accommadation and gastric emptying (83).

545 Glucoregulatory hormones (e.g. GLP-1, GIP, insulin) and the slowing of gastric emptying are 546 key determinants of postprandial glycemia. Bitter tastants have been shown to stimulate the 547 secretion of the incretin hormone GLP-1 from EEC cell lines (30, 48), while in mice gavage 548 of bitter gourd extract (84) or denatonium benozate (30) stimulates GLP-1 and subsequent 549 insulin secretion, leading to lowering of blood glucose. A recent study in healthy men also 550 demonstrated that intragastric and intraduodenal administration of the bitter tastant quinine 551 similarly lowered plasma glucose, increased plasma insulin and GLP-1, and slowed gastric

emptying (40). The current data also demonstrate an enhancement in the postprandial GLP-1 552 response following gastric and duodenal targeting of hop extract. However, this response was 553 accompanied by a substantial reduction in the postprandial insulin response, with little 554 change in plasma glucose compared with that in the placebo. Interestingly, GIP, the only gut 555 peptide hormone measured that is secreted from the enteroendocrine K-cell subtype, also 556 557 exhibited a substantial reduction in postprandial response following hop treatments. This is contrast to the observed stimulation of CCK, GLP-1 and PYY producing EECs, suggesting 558 that K-cells lack the appropriate T2Rs. 559

560 GIP has been shown to be responsible for the majority of the incretin effect in healthy

subjects, affecting glycemic levels during the whole postprandial period (85). In contrast,

562 GLP-1 primarily affects glycaemic regulation in the early postprandial phase, delaying gastric

563 emptying and reducing plasma glucagon levels (85). GIP has also recently been demonstrated

as a PP secretagogue (85, 86). Hence the suppression of postparndial GIP in the hop

treatment groups may in part explain the suppression of insulin and PP observed.

566 GIP secretion is driven primarly by the rate of macronutrient delivery from the stomach to

the duodenum (i.e. rate of gastric emptying) (87). Any delay in gastric emptying in the

absence of a treatment induced-stimulation would potentially result in this observed decrease

569 (88-90). Although this study did not measure gastric emptying *per se*, an established action of

570 CCK, GLP-1 and PYY is to delay gastric emptying (91-93). Importantly, regulation of

571 postprandial glycemia was maintained despite reductions in GIP and insulin, indicating a

572 metabolic shift towards greater insulin sensitivity, a possible consequence of increased GLP-

573 1 secretion. Replication of these results using a fixed energy meal would be ideal, as this

would remove any influence from the inter-treatment differences in absolute energy intake

that occurred at the *ad libitum* meals.

576 Off-target effects of Amarasate[®] treatments included small (<10 mm) but significant

577 increases in subjective ratings of nausea, bloating and abdominal discomfort, which are

578 consistent with known effects of CCK, GLP-1 and PYY on upper gastrointestinal sensations

579 (94, 95). The known sedative activity of hop bitter acids may also have contributed to the

small decline in subjective ratings of energy following Amarasate[®] treatment (96, 97),

although no corresponding effect on relaxation was observed. Virtually all reported adverse

582 symptoms were associated with gastric targeting of the hops extract, with 32% of participants

583 in this treatment reporting an acute bout of mild- to moderate-intensity diarrhea. Targeting

delivery to the small intestine improved tolerance of the hop treatment, suggesting that gastric

585 T2Rs may play a key role in detection of ingested toxins, stimulating a host defence

586 mechanism involving net secretion of fluid and electrolytes into the intestinal lumen,

587 accelerating intestinal transit to flush harmful compounds from the GI tract in a process

similar to that described for T2Rs in the human and rat large intestine (98). Further

589 optimisation of the dosage of hops extract used and its timing relative to meals may also

- 590 contribute to a reduction in the side-effect profile.
- 591 The Amarasate[®] extract used in the current study is a supercritical CO_2 extract of hop
- 592 containing a number of hop bitter acids (e.g. cohumulone, humulone, adhumulone,
- colupulone, lupulone and adlupulone). These α- and β-acids are potent ligands for hT2R-1,

⁵⁹⁴ 14 and 40, exhibiting reported thresholds of activation as low as 3 nM (47). All three hop-

responsive hT2Rs have previously been identified in either the small (31) or large intestine

596 (99, 100). However, little is known regarding the profile of hT2Rs expression in specific EEC

cell-types. The functional data from the current study would suggest CCK, GLP-1, PYY and

598 ghrelin-producing EECs express T2R-1, 14 or 40, a T2R expression profile not shared by

599 GIP-producing EECs.

600 It is worth noting that other compounds derived from hops acids have previously been

601 examined as anti-obesity targets, and potential exists for overlapping or synergistic

602 mechanisms of action. Oxidised hop bitter acid extracts have been reported by Morimoto-

603 Kobayashi et al. to reduce fat mass in an overweight population through increased brown

adipose tissue thermogenesis (55, 56), with recent work in rats suggesting CCK secretion as a

potential mediator of this bioactivity (32). Isomerised α -acids and their derivatives have also

shown anti-obesogenic effects, putatively *via* metabolic regulation (39, 50), although a recent

report in mice highlighted a possible role for the T2Rs and anorexigenic hormones (48). Kok

et al. (48) showed that the synthetic substituted 1,3-cyclopentadione isomerised alpha acid

derivative KDT501 (KinDex Pharmaceuticals) activated T2R1 *in vitro* and when

administered to mice resulted in increased GLP-1, CCK and ghrelin plasma concentrations,

611 and improved glucose and insulin responses.

612 Some limitations of our study should be noted. Targeted delivery of Amarasate[®] to the

613 duodenum may not have occurred in all cases, as the press-fit delayed-release capsules used,

614 can leak (101) or disassemble (102) under gastric conditions *in vitro*. In addition, the short

- 615 intervals between the *ad libitum* lunch, snack and end of daily monitoring may have
- 616 prevented appropriate treatment differences developing in appetitive VAS measures such as
- 617 hunger, fullness and prospective consumption (57). The study could also have benefited from

618 the inclusion of measures of gastric emptying. However, GIP secretion is dependent upon nutrient delivery to the duodenum (103) and indirectly supports delayed gastric emptying as a 619 mechanism of action. Another limitation of the study was our inclusion of only healthy-620 weight males as paticipants, done to exclude the potentially confounding effects of the 621 622 menstrual cycle on energy intake (104) and to ensure robust appetite and glycaemic regulatory mechanisms (9-13). Finally, the effect of repetitive or chronic administration of 623 hop extract on appetite regulation, including possible compensatory mechanisms and effects 624 on weight management, are unknown. Thus, further long-term studies are warranted. 625 In conclusion, both gastric and duodenal delivery of Amarasate[®], a bitter hop extract, 626 suppressed total EI and enhanced pre-meal ghrelin and postprandial CCK, GLP-1 and PYY 627 responses, providing a potential "bitter brake" on energy intake in healthy-weight males. 628 These changes occurred without significant effects on subjective measures of appetite or on 629 any measure of the hedonistic properties of the test meals though small but significant 630 increases were observed in some measures of gastrointestoinal discomfort. Changes in 631 632 glycaemic regulation were also observed, with reductions in postprandial insulin, PP and GIP responses without a significant effect on the glycaemic response to the *ad libitium* test meals. 633 These data highlight the potential of hop compounds as novel therapeutics to regulate both 634 acute energy intake and glycaemic regulation via modulation of gut peptide release and 635 636 delayed gastric emptying. Further studies investigating the longer-term effects of lower doses of hop extract as a tool for improved weight management and glycemic regulation should be 637 conducted, to determine potential efficacy. 638

639 **6.** Acknowledgements

- 640 The authors thank the individuals who kindly agreed to be participants in the clinical trial.
- 641 We would also like to thank the nurse practitioners who assisted with blood sampling during
- the clinical trial, Dr Raina Wong for assistance with hormone analysis, Dr Ron Beatson and
- Dave Anderson for their assistance with hops analysis and selection, and Dr Russell
- 644 Walmsley for providing medical oversight for this trial. We also thank Prof. Richard
- 645 Newcomb, Dr Roger Harker and Dr Pramod Gopal for review of the manuscript. This
- 646 research was funded by the New Zealand Government (NZ Ministry of Business, Innovation
- 647 & Employment, contract C11X1004).

648 7. Author Contributions

- 649 Contributor roles (Credit, CASRAI): conceptualization and supervision: JI; funding
- acquisition: KS, JI; methodology: EW, JI and SP; project administration EW; investigation:
- 651 EW, KL, MP, HS, CL, KS and JI; data curation: JI; formal analysis MW; visualisation: EW
- and JI; Writing original draft: EW, SP and JI; Writing review & editing: All Authors.

653 8. Conflict of Interest

EW, MP, KL, CL, KS, JI are employees of The New Zealand Institute for Plant and Food 654 Research Ltd, a New Zealand Government-owned Crown Research Institute, which has a 655 royalty agreement associated with sales of the Amarasate[®] extract. The authors declare that 656 there is no individual personal financial relationship and they gain no financial incentive or 657 royalty payment outside of salaries for their employment. SDP and HS declare no conflict of 658 interest related to this product. The sponsors had no role in the design of the study, the 659 collection, analyses, or interpretation of data, in the writing of the manuscript, or in the 660 decision to publish the results. 661

663 9. References

- Verboven K, Hansen D. Critical Reappraisal of the Role and Importance of Exercise
 Intervention in the Treatment of Obesity in Adults. Sports Med 2021;51(3):379-89. doi:
 10.1007/s40279-020-01392-8.
- 667 2. Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and Cancer-
- 668 Related Mortality. Physiol Rev 2015;95(3):727-48. doi: 10.1152/physrev.00030.2014.
- 6693.Lovren F, Teoh H, Verma S. Obesity and atherosclerosis: mechanistic insights. Can J Cardiol6702015;31(2):177-83. doi: 10.1016/j.cjca.2014.11.031.
- 4. Deng T, Lyon CJ, Bergin S, Caligiuri MA, Hsueh WA. Obesity, Inflammation, and Cancer. Annu
 672 Rev Pathol 2016;11:421-49. doi: 10.1146/annurev-pathol-012615-044359.
- 673 5. Himbert C, Delphan M, Scherer D, Bowers LW, Hursting S, Ulrich CM. Signals from the
 674 Adipose Microenvironment and the Obesity-Cancer Link-A Systematic Review. Cancer Prev
 675 Res (Phila) 2017;10(9):494-506. doi: 10.1158/1940-6207.CAPR-16-0322.
- 676 6. Park J, Morley TS, Kim M, Clegg DJ, Scherer PE. Obesity and cancer--mechanisms underlying
 677 tumour progression and recurrence. Nat Rev Endocrinol 2014;10(8):455-65. doi:
 678 10.1038/nrendo.2014.94.
- van der Wielen N, van Avesaat M, de Wit NJW, Vogels JTWE, Troost F, Masclee A, Koopmans
 S-J, van der Meulen J, Boekschoten MV, Müller M, et al. Cross-Species Comparison of Genes
 Related to Nutrient Sensing Mechanisms Expressed along the Intestine. PloS one
 2014;9(9):e107531. doi: 10.1371/journal.pone.0107531.
- 6838.Reimann F, Tolhurst G, Gribble FM. G-protein-coupled receptors in intestinal684chemosensation. Cell metabolism 2012;15(4):421-31. doi: 10.1016/j.cmet.2011.12.019.
- Benedict C, Axelsson T, Soderberg S, Larsson A, Ingelsson E, Lind L, Schioth HB. Fat mass and
 obesity-associated gene (FTO) is linked to higher plasma levels of the hunger hormone
 ghrelin and lower serum levels of the satiety hormone leptin in older adults. Diabetes
 2014;63(11):3955-9. doi: 10.2337/db14-0470.
- Llewellyn CH, Trzaskowski M, van Jaarsveld CM, Plomin R, Wardle J. Satiety mechanisms in
 genetic risk of obesity. JAMA Pediatrics 2014;168(4):338-44. doi:
 10.1001/jamapediatrics.2013.4944.
- Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1
 secretion in obesity: cause or consequence? Gut 1996;38(6):916-9.
- Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR.
 Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med
 2003;349(10):941-8. doi: 10.1056/NEJMoa030204.
- Lean MEJ, Malkova D. Altered gut and adipose tissue hormones in overweight and obese
 individuals: cause or consequence? International journal of obesity 2016;40(4):622-32. doi:
 10.1038/ijo.2015.220.
- Das SK, Gilhooly CH, Golden JK, Pittas AG, Fuss PJ, Dallal GE, McCrory MA, Saltzman E,
 Roberts SB. Long Term Effects of Energy-Restricted Diets Differing in Glycemic Load on
 Metabolic Adaptation and Body Composition. Open Nutr J 2007;85(4):1023-30.
- Del Corral P, Chandler-Laney PC, Casazza K, Gower BA, Hunter GR. Effect of Dietary
 Adherence with or without Exercise on Weight Loss: A Mechanistic Approach to a Global
 Problem. J Clin Endocrinol Metab 2009;94(5):1602-7. doi: 10.1210/jc.2008-1057.
- Redman LM, Heilbronn LK, Martin CK, Alfonso A, Smith SR, Ravussin E. Effect of Calorie
 Restriction with or without Exercise on Body Composition and Fat Distribution. The Journal
 of Clinical Endocrinology & Metabolism 2007;92(3):865-72. doi: 10.1210/jc.2006-2184.
- 709 17. Chaput JP, Doucet E, Tremblay A. Obesity: a disease or a biological adaptation? An update.
 710 Obes Rev 2012;13(8):681-91. doi: 10.1111/j.1467-789X.2012.00992.x.
- 18. le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, Lonroth H,
 Fandriks L, Ghatei MA, Bloom SR, et al. Gut hormones as mediators of appetite and weight

/13		loss after Roux-en-Y gastric bypass. Ann Surg 2007;246(5):780-5. doi:
714	4.0	
715	19.	Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, Trautmann M.
/16		Effects of exenatide and lifestyle modification on body weight and glucose tolerance in
/1/		obese subjects with and without pre-diabetes. Diabetes care 2010;33(6):1173-5. doi:
/18	20	
719	20.	SKOV AR, Toubro S, Ronn B, Hoim L, Astrup A. Randomized trial on protein vs carbonydrate in
720		ad libitum fat reduced diet for the treatment of obesity. International journal of obesity and
721		related metabolic disorders : journal of the international Association for the Study of Obesity
722	21	1999;23(5):528-30.
723	21.	Breen DM, Rasmussen BA, Cole CD, Jackson VM, Lam TKT. Nutrient-Sensing Mechanisms in
724		the Gut as Therapeutic Targets for Diabetes. Diabetes 2013;62(9):3005-13. doi:
725	22	10.2337/0013-0523.
720	ZZ.	Reimann F, Gribble FM. G protein-coupled receptors as new therapeutic targets for type 2
727	22	diabetes. Diabetologia 2016;59:229-33. doi: 10.1007/s00125-015-3825-2.
728	23.	Janssen S, Depoortere I. Nutrient sensing in the gut: new roads to therapeutics? Trends in
729		Endocrinology & Metabolism 2013;24(2).92-100. doi:
750	24	Represe M. Meyerbef W. Oral and extraoral bitter tasta recenters. Results Probl Cell Differ
751	24.	2010-52:97 00 doi: 10 1007/078 2 642 14426 4 8
732	25	Clark AA Liggett SB Munger SD Extraoral bitter taste recentors as mediators of off-target
733	25.	drug effects EASER 1 2012;26(12):4827-31 doi: 10.1096/fi 12-215087
735	26	laggunilli A Singh N Unadhyaya I Sikarwar AS Arakawa M Dakshinamurti S Bhullar RP
736	20.	Duan K Chelikani P Analysis of the expression of human hitter taste recentors in extraoral
737		tissues Mol Cell Biochem 2017:426(1-2):137-47 doi: 10.1007/s11010-016-2902-z
738	27	Soranzo N. Bufe B. Sabeti PC. Wilson IF. Weale MF. Marguerie R. Meverhof W. Goldstein DB.
739	_/.	Positive selection on a high-sensitivity allele of the human bitter-taste receptor TAS2R16.
740		Curr Biol 2005:15(14):1257-65. doi: 10.1016/i.cub.2005.06.042.
741	28.	Sandell MA. Breslin PAS. Variability in a taste-receptor gene determines whether we taste
742		toxins in food. Curr Biol 2006;16(18):R792-R4. doi: DOI 10.1016/j.cub.2006.08.049.
743	29.	Chen MC, Wu SV, Reeve JR, Jr., Rozengurt E. Bitter stimuli induce Ca2+ signaling and CCK
744		release in enteroendocrine STC-1 cells: role of L-type voltage-sensitive Ca2+ channels. Am J
745		Physiol Cell Physiol 2006;291(4):C726-39. doi: 10.1152/ajpcell.00003.2006.
746	30.	Kim KS, Egan JM, Jang HJ. Denatonium induces secretion of glucagon-like peptide-1 through
747		activation of bitter taste receptor pathways. Diabetologia 2014;57(10):2117-25. doi:
748		10.1007/s00125-014-3326-5.
749	31.	Le Neve B, Foltz M, Daniel H, Gouka R. The steroid glycoside H.g12 from Hoodia gordonii
750		activates the human bitter receptor TAS2R14 and induces CCK release from HuTu-80 cells.
751		Am J Physiol Gastrointest Liver Physiol 2010;299(6):G1368-75. doi:
752		10.1152/ajpgi.00135.2010.
753	32.	Yamazaki T, Morimoto-Kobayashi Y, Koizumi K, Takahashi C, Nakajima S, Kitao S, Taniguchi Y,
754		Katayama M, Ogawa Y. Secretion of a gastrointestinal hormone, cholecystokinin, by hop-
755		derived bitter components activates sympathetic nerves in brown adipose tissue. J Nutr
756		Biochem 2018;64:80-7. doi: 10.1016/j.jnutbio.2018.10.009.
757	33.	Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R,
758		Conen D, Beglinger C. Glucagon-like peptide-1: a potent regulator of food intake in humans.
759		Gut 1999;44(1):81-6.
760	34.	Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP. C-terminal octapeptide of cholecystokinin
761		decreases food intake in man. Am J Clin Nutr 1981;34(2):154-60. doi: 10.1093/ajcn/34.2.154.

Goebel-Stengel M, Stengel A, Wang L, Ohning G, Tache Y, Reeve JR, Jr. CCK-8 and CCK-58

differ in their effects on nocturnal solid meal pattern in undisturbed rats. Am J Physiol Regul

762

763

35.

764 Integr Comp Physiol 2012;303(8):R850-60. doi: 10.1152/ajpregu.00365.2011. 765 36. Schwartz GJ. The role of gastrointestinal vagal afferents in the control of food intake: current 766 prospects. Nutrition 2000;16(10):866-73. 767 37. Skibicka KP. The central GLP-1: implications for food and drug reward. Front Neurosci 2013;7:181. doi: 10.3389/fnins.2013.00181. 768 769 Bitarafan V, Fitzgerald PCE, Little TJ, Meyerhof W, Jones KL, Wu T, Horowitz M, Feinle-Bisset 38. 770 C. Intragastric administration of the bitter tastant quinine lowers the glycemic response to a 771 nutrient drink without slowing gastric emptying in healthy men. Am J Physiol Regul Integr 772 Comp Physiol 2020;318(2):R263-R73. doi: 10.1152/ajpregu.00294.2019. 773 39. Obara K, Mizutani M, Hitomi Y, Yajima H, Kondo K. Isohumulones, the bitter component of 774 beer, improve hyperglycemia and decrease body fat in Japanese subjects with prediabetes. 775 Clin Nutr 2009;28(3):278-84. doi: 10.1016/j.clnu.2009.03.012. 776 40. Rose BD, Bitarafan V, Rezaie P, Fitzgerald PCE, Horowitz M, Feinle-Bisset C. Comparative 777 Effects of Intragastric and Intraduodenal Administration of Quinine on the Plasma Glucose 778 Response to a Mixed-Nutrient Drink in Healthy Men: Relations with Glucoregulatory 779 Hormones and Gastric Emptying. J Nutr 2021. doi: 10.1093/jn/nxab020. 780 41. Deloose E, Janssen P, Corsetti M, Biesiekierski J, Masuy I, Rotondo A, Van Oudenhove L, 781 Depoortere I, Tack J. Intragastric infusion of denatonium benzoate attenuates interdigestive 782 gastric motility and hunger scores in healthy female volunteers. Am J Clin Nutr 783 2017;105(3):580-8. doi: 10.3945/ajcn.116.138297. 784 42. Iven J, Biesiekierski JR, Zhao D, Deloose E, O'Daly OG, Depoortere I, Tack J, Van Oudenhove L. 785 Intragastric quinine administration decreases hedonic eating in healthy women through 786 peptide-mediated gut-brain signaling mechanisms. Nutr Neurosci 2019;22(12):850-62. doi: 787 10.1080/1028415X.2018.1457841. 788 43. van Avesaat M, Troost FJ, Ripken D, Peters J, Hendriks HF, Masclee AA. Intraduodenal 789 infusion of a combination of tastants decreases food intake in humans. Am J Clin Nutr 790 2015;102(4):729-35. doi: 10.3945/ajcn.115.113266. 791 44. Bitarafan V, Fitzgerald PCE, Little TJ, Meyerhof W, Wu T, Horowitz M, Feinle-Bisset C. Effects 792 of Intraduodenal Infusion of the Bitter Tastant, Quinine, on Antropyloroduodenal Motility, 793 Plasma Cholecystokinin, and Energy Intake in Healthy Men. Journal of 794 neurogastroenterology and motility 2019;25(3):413-22. doi: 10.5056/jnm19036. 795 45. Little TJ, Gupta N, Case RM, Thompson DG, McLaughlin JT. Sweetness and bitterness taste of 796 meals per se does not mediate gastric emptying in humans. Am J Physiol Regul Integr Comp 797 Physiol 2009;297(3):R632-9. doi: 10.1152/ajpregu.00090.2009. 798 46. Andreozzi P, Sarnelli G, Pesce M, Zito FP, Alessandro AD, Verlezza V, Palumbo I, Turco F, 799 Esposito K, Cuomo R. The Bitter Taste Receptor Agonist Quinine Reduces Calorie Intake and 800 Increases the Postprandial Release of Cholecystokinin in Healthy Subjects. Journal of 801 neurogastroenterology and motility 2015;21(4):511-9. doi: 10.5056/jnm15028. 802 47. Intelmann D, Batram C, Kuhn C, Haseleu G, Meyerhof W, Hofmann T. Three TAS2R Bitter 803 Taste Receptors Mediate the Psychophysical Responses to Bitter Compounds of Hops (Humulus lupulus L.) and Beer. Chem Percept 2009;2(3):118-32. doi: 10.1007/s12078-009-804 805 9049-1. Kok BP, Galmozzi A, Littlejohn NK, Albert V, Godio C, Kim W, Kim SM, Bland JS, Grayson N, 806 48. 807 Fang M, et al. Intestinal bitter taste receptor activation alters hormone secretion and 808 imparts metabolic benefits. Mol Metab 2018;16:76-87. doi: 10.1016/j.molmet.2018.07.013. 809 49. Yajima H, Noguchi T, Ikeshima E, Shiraki M, Kanaya T, Tsuboyama-Kasaoka N, Ezaki O, 810 Oikawa S, Kondo K. Prevention of diet-induced obesity by dietary isomerized hop extract 811 containing isohumulones, in rodents. International journal of obesity 2005;29(8):991-7. doi: 812 10.1038/sj.ijo.0802965.

813 814 815	50.	Yajima H, Ikeshima E, Shiraki M, Kanaya T, Fujiwara D, Odai H, Tsuboyama-Kasaoka N, Ezaki O, Oikawa S, Kondo K. Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance.
816 817 818 819 820	51.	J Biol Chem 2004;279(32):33456-62. doi: 10.1074/JbC.M403456200. Vroegrijk IO, van Diepen JA, van den Berg SA, Romijn JA, Havekes LM, van Dijk KW, Darland G, Konda V, Tripp ML, Bland JS, et al. META060 protects against diet-induced obesity and insulin resistance in a high-fat-diet fed mouse. Nutrition 2013;29(1):276-83. doi: 10.1016/i.nut.2012.05.004.
821 822 823 824	52.	Tripp ML, Darland G, Konda VR, Pacioretty LM, Chang JL, Bland JS, Babish JG. Optimized mixture of hops rho iso-alpha acids-rich extract and acacia proanthocyanidins-rich extract reduces insulin resistance in 3T3-L1 adipocytes and improves glucose and insulin control in db/db mice. Nutr Res Pract 2012;6(5):405-13. doi: 10.4162/nrp.2012.6.5.405.
825 826 827	53.	Sumiyoshi M, Kimura Y. Hop (Humulus lupulus L.) extract inhibits obesity in mice fed a high- fat diet over the long term. Br J Nutr 2013;109(1):162-72. doi: 10.1017/S000711451200061X
828 829 830	54.	Everard A, Geurts L, Van Roye M, Delzenne NM, Cani PD. Tetrahydro iso-alpha acids from hops improve glucose homeostasis and reduce body weight gain and metabolic endotoxemia in high-fat diet-fed mice. PloS one 2012;7(3):e33858. doi:
831 832 833 834	55.	10.1371/Journal.pone.0033858. Morimoto-Kobayashi Y, Ohara K, Takahashi C, Kitao S, Wang G, Taniguchi Y, Katayama M, Nagai K. Matured Hop Bittering Components Induce Thermogenesis in Brown Adipose Tissue via Sympathetic Nerve Activity. PloS one 2015;10(6):e0131042. doi:
835 836 837 838 838	56.	Morimoto-Kobayashi Y, Ohara K, Ashigai H, Kanaya T, Koizumi K, Manabe F, Kaneko Y, Taniguchi Y, Katayama M, Kowatari Y, et al. Matured hop extract reduces body fat in healthy overweight humans: a randomized, double-blind, placebo-controlled parallel group study.
839 840 841 842	57.	Walker E, Lo K, Tham S, Pahl M, Lomiwes D, Cooney J, Wohlers M, Gopal P. New Zealand Bitter Hops Extract Reduces Hunger During a 24 h Water Only Fast. Nutrients 2019;11(11). doi: 10.3390/nu11112754.
843 844	58.	Williams EJ. Experimental Designs Balanced for the Estimation of Residual Effects of Treatments. Australian Journal of Chemistry 1949;2(2):149-68. doi: 10.1071/ch9490149.
845 846 847 848	59. 60.	John PWM. Statisitcal Design and Analysis of Experiments. New York: Macmillan, 1971. Blundell J, de Graaf C, Hulshof T, Jebb S, Livingstone B, Lluch A, Mela D, Salah S, Schuring E, van der Knaap H, et al. Appetite control: methodological aspects of the evaluation of foods. Obes Rev 2010;11(3):251-70. doi: 10.1111/j.1467-789X.2010.00714.x.
849 850	61.	Amo R. DRcaps [®] Capsules Achieve Delayed Release Properties for Nutritional Ingredients in Human Clinical Study. Capsugel, 2014. no. BAS 420.]
851 852	62.	Committee EBCA. Analytica EBC, European Brewery Convention, Method 7.8. 5th ed. Nürnberg: Verlag Hans Carl Getränke-Fachverlag, 1998.
853 854	63.	Tucci SA. Phytochemicals in the Control of Human Appetite and Body Weight. Pharmaceuticals (Basel) 2010;3(3):748-63. doi: 10.3390/ph3030748.
855 856 857	64.	Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. International journal of obesity 2000;24(1):38-48.
858 859 860	65.	Bovenschen HJ, Janssen MJR, van Oijen MGH, Laheij RJF, van Rossum LGM, Jansen JBMJ. Evaluation of a gastrointestinal symptoms questionnaire. Digest Dis Sci 2006;51(9):1509-15. doi: 10.1007/s10620-006-9120-6.
861 862	66.	McNair DM, Lorr M, Droppelman LF. Manual for the profile of mood states. San Diego, CA.: Educational and Industrial Testing Service, 1971.

	67	
863	67.	Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-
864		term weight gain in women and men. N Engl J Med 2011;364(25):2392-404. doi:
865		10.1056/NEJMoa1014296.
866	68.	Mennella I, Fogliano V, Ferracane R, Arlorio M, Pattarino F, Vitaglione P. Microencapsulated
867		bitter compounds (from Gentiana lutea) reduce daily energy intakes in humans. Br J Nutr
868		2016;116:1841-50. doi: 10.1017/s0007114516003858.
869	69.	Bitarafan V, Fitzgerald PCE, Little TJ, Meyerhof W, Wu T, Horowitz M, Feinle-Bisset C. Effects
870		of Intraduodenal Infusion of the Bitter Tastant, Quinine, on Antropyloroduodenal Motility,
871		Plasma Cholecystokinin, and Energy Intake in Healthy Men. Journal of
872		neurogastroenterology and motility 2019. doi: 10.5056/jnm19036.
873	70.	Steinert RE, Feinle-Bisset C, Asarian L, Horowitz M, Beglinger C, Geary N. Ghrelin, CCK, GLP-1,
874		and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health,
875		Obesity, and After RYGB. Physiol Rev 2017;97(1):411-63. doi: 10.1152/physrev.00031.2014.
876	71.	Lim JJ, Poppitt SD. How Satiating Are the 'Satiety' Peptides: A Problem of Pharmacology
877		versus Physiology in the Development of Novel Foods for Regulation of Food Intake.
878		Nutrients 2019;11(7). doi: 10.3390/nu11071517.
879	72.	Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa
880		K, Nakazato M. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized
881		in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans.
882		Endocrinology 2000;141(11):4255-61. doi: 10.1210/endo.141.11.7757.
883	73.	Wang HT, Lu QC, Wang Q, Wang RC, Zhang Y, Chen HL, Zhao H, Qian HX. Role of the
884		duodenum in regulation of plasma ghrelin levels and body mass index after subtotal
885		gastrectomy. World J Gastroenterol 2008;14(15):2425-9. doi: 10.3748/wjg.14.2425.
886	74.	Muller-Lissner SA, Fimmel CJ, Sonnenberg A, Will N, Muller-Duysing W, Heinzel F, Muller R,
887		Blum AL. Novel approach to quantify duodenogastric reflux in healthy volunteers and in
888		patients with type I gastric ulcer. Gut 1983:24(6):510-8.
889	75.	Janssen S. Laermans J. Verhulst PJ. Thiis T. Tack J. Depoortere I. Bitter taste receptors and
890		alpha-gustducin regulate the secretion of ghrelin with functional effects on food intake and
891		gastric emptying. Proc Natl Acad Sci U S A 2011:108(5):2094-9. doi:
892		10.1073/pnas 1011508108
893	76.	Deloose F. Corsetti M. Van Oudenhove I. Depoortere I. Tack I. Intragastric infusion of the
894	/0.	bitter tastant quinine suppresses hormone release and antral motility during the fasting
895		state in healthy female volunteers. Neurogastroenterol Motil 2018:30(1) doi:
896		10 1111/nmo 13171
897	77	Sadoul BC Schuring FA Mela DI Peters HP. The relationship between annetite scores and
808	//.	subsequent energy intake: an analysis based on 23 randomized controlled studies. Annetite
800		2014.83.152-9 doi: 10.1016/i annet 2014.08.016
000	79	Ponnitt SD Han S Strik CM Kindleysides S Chan VK Investigating acute satiation and meal
900 901	70.	termination effects of a commercial linid emulsion: A breakfast meal study. Physiology &
002		behavior 2015:152/Pt A):20-5, doi: 10.1016/i.physheb.2015.09.008
002	70	Deloose E. Corsetti M. Van Oudenboye I. Denoortere I. Tack IE. In man intragastric
903	79.	administration of the hitter compound depatonium benzaate decreases hunger and the
904 005		administration of the bitter compound denatorium benzoate decreases hunger and the
905		
900	00	10.1010/30010-3083(13)02032-0.
907	00.	Pitter Tasta Pacanter Aganist Denatonium Panaesta on Castria Emptying Satisfy and Pature
308		of Hunder After a Meal in Healthy Volunteers, Costroonterslaw, 2012;144/5/5549
909	01	Or nunger Arter a Wiedrin meditiny volumeers. Gastroenterology 2013;144(5):5548.
910	δ1.	Avau D, Rotonuo A, Thijs T, Anurews CN, Janssen P, Tack J, Depoortere I. Targeting extra-oral
911		Differences and the second sec
917		2015;5:15985. doi: 10.1038/Srep15985.

913 82. Iven J, Biesiekierski JR, Zhao D, Deloose E, O'Daly OG, Depoortere I, Tack J, Van Oudenhove L. 914 Intragastric quinine administration decreases hedonic eating in healthy women through 915 peptide-mediated gut-brain signaling mechanisms. Nutr Neurosci 2018:1-13. doi: 916 10.1080/1028415x.2018.1457841. 917 83. Piessevaux H, Tack J, Walrand S, Pauwels S, Geubel A. Intragastric distribution of a 918 standardized meal in health and functional dyspepsia: correlation with specific symptoms. 919 Neurogastroenterol Motil 2003;15(5):447-55. doi: 10.1046/j.1365-2982.2003.00431.x. 920 Huang TN, Lu KN, Pai YP, Chin H, Huang CJ. Role of GLP-1 in the Hypoglycemic Effects of Wild 84. 921 Bitter Gourd. Evid Based Complement Alternat Med 2013;2013:625892. doi: 922 10.1155/2013/625892. 923 85. Gasbjerg LS, Helsted MM, Hartmann B, Jensen MH, Gabe MBN, Sparre-Ulrich AH, Veedfald S, 924 Stensen S, Lanng AR, Bergmann NC, et al. Separate and Combined Glucometabolic Effects of 925 Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in 926 Healthy Individuals. Diabetes 2019;68(5):906-17. doi: 10.2337/db18-1123. 927 86. Veedfald S, Vedtofte L, Skov-Jeppesen K, Deacon CF, Hartmann B, Vilsboll T, Knop FK, 928 Christensen MB, Holst JJ. Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic 929 Polypeptide Secretagogue in Humans. J Clin Endocrinol Metab 2020;105(3):e502-e10. doi: 930 10.1210/clinem/dgz097. 931 87. Pilichiewicz AN, Chaikomin R, Brennan IM, Wishart JM, Rayner CK, Jones KL, Smout AJ, 932 Horowitz M, Feinle-Bisset C. Load-dependent effects of duodenal glucose on glycemia, 933 gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men. 934 Am J Physiol Endocrinol Metab 2007;293(3):E743-53. doi: 10.1152/ajpendo.00159.2007. 935 88. Wilson RM, Boden G, Owen OE. Pancreatic polypeptide responses to a meal and to 936 intraduodenal amino acids and sodium oleate. Endocrinology 1978;102(3):859-63. doi: 937 10.1210/endo-102-3-859. 938 89. Batterham RL, Le Roux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, Frost GS, Ghatei MA, 939 Bloom SR. Pancreatic polypeptide reduces appetite and food intake in humans. J Clin 940 Endocrinol Metab 2003;88(8):3989-92. doi: 10.1210/jc.2003-030630. 941 90. Krarup T, Holst JJ, Larsen KL. Responses and molecular heterogeneity of IR-GIP after 942 intraduodenal glucose and fat. Am J Physiol 1985;249(2 Pt 1):E195-200. doi: 943 10.1152/ajpendo.1985.249.2.E195. 944 91. Yamagishi T, Debas HT. Cholecystokinin inhibits gastric emptying by acting on both proximal 945 stomach and pylorus. Am J Physiol 1978;234(4):E375-8. doi: 946 10.1152/ajpendo.1978.234.4.E375. 947 92. Naslund E, Bogefors J, Gryback P, Bjellerup P, Jacobsson H, Holst JJ, Hellstrom PM. GLP-1 948 inhibits gastric emptying of water but does not influence plasma. Scand J Gastroenterol 949 2001;36(2):156-62. 950 93. Naslund E, Bogefors J, Skogar S, Gryback P, Jacobsson H, Holst JJ, Hellstrom PM. GLP-1 slows 951 solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 952 1999;277(3):R910-6. doi: 10.1152/ajpregu.1999.277.3.R910. 953 94. Fried M, Feinle C. The role of fat and cholecystokinin in functional dyspepsia. Gut 2002;51 954 Suppl 1:i54-7. doi: 10.1136/gut.51.suppl 1.i54. 955 Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and 95. 956 diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 957 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes Metab 2017;19(3):336-47. doi: 10.1111/dom.12824. 958 959 96. Franco L, Sanchez C, Bravo R, Rodriguez AB, Barriga C, Romero E, Cubero J. The sedative 960 effect of non-alcoholic beer in healthy female nurses. PloS one 2012;7(7):e37290. doi: 961 10.1371/journal.pone.0037290. 962 97. Zanoli P, Zavatti M. Pharmacognostic and pharmacological profile of Humulus lupulus L. 963 Journal of ethnopharmacology 2008;116(3):383-96. doi: 10.1016/j.jep.2008.01.011.

964	98.	Kaji I, Karaki S, Fukami Y, Terasaki M, Kuwahara A. Secretory effects of a luminal bitter
965		tastant and expressions of bitter taste receptors, T2Rs, in the human and rat large intestine.
966		Am J Physiol Gastrointest Liver Physiol 2009;296(5):G971-81. doi: 10.1152/ajpgi.90514.2008.
967	99.	Rozengurt N, Wu SV, Chen MC, Huang C, Sternini C, Rozengurt E. Colocalization of the alpha-
968		subunit of gustducin with PYY and GLP-1 in L cells of human colon. Am J Physiol Gastrointest
969		Liver Physiol 2006;291(5):G792-802. doi: 10.1152/ajpgi.00074.2006.
970	100.	Kaji I, Karaki S-i, Fukami Y, Terasaki M, Kuwahara A. Secretory effects of a luminal bitter
971		tastant and expressions of bitter taste receptors, T2Rs, in the human and rat large intestine.
972		Am J Physiol Gastrointest Liver Physiol 2009;296(5):G971-81. doi: 10.1152/ajpgi.90514.2008.
973	101.	Al-Tabakha MM, Arida AI, Fahelelbom KMS, Sadek B, Abu Jarad RA. Performances of New
974		Generation of Delayed Release Capsules. J Young Pharm 2015;7(1):36-44. doi:
975		10.5530/jyp.2015.1.7.
976	102.	Miller DS, Parsons AM, Bresland J, Herde P, Pham DM, Tan A, Hsu HY, Prestidge CA, Kuchel T,
977		Begg R, et al. A simple and inexpensive enteric-coated capsule for delivery of acid-labile
978		macromolecules to the small intestine. J Zhejiang Univ Sci B 2015;16(7):586-92. doi:
979		10.1631/jzus.B1400290.
980	103.	Reimann F, Diakogiannaki E, Moss CE, Gribble FM. Cellular mechanisms governing glucose-
981		dependent insulinotropic polypeptide secretion. Peptides 2020;125:170206. doi:
982		10.1016/j.peptides.2019.170206.
983	104.	Brennan IM, Feltrin KL, Nair NS, Hausken T, Little TJ, Gentilcore D, Wishart JM, Jones KL,
984		Horowitz M, Feinle-Bisset C. Effects of the phases of the menstrual cycle on gastric
985		emptying, glycemia, plasma GLP-1 and insulin, and energy intake in healthy lean women. Am
986		J Physiol Gastrointest Liver Physiol 2009;297(3):G602-10. doi: 10.1152/ajpgi.00051.2009.